ACTINOGEN MEDICAL LIMITED — Director's Dealing 2021

Dec 20, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Introduced 30/9/2001.
Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr George Morstyn
Date of last notice	18 November 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	1. Direct2. Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.	2. HSBC Custody Nominees (Australia) Limited <A/C 2> -beneficiary
Date of change	20 December 2021
No. of securities held priorto change	1. 1,000,000 fully paid ordinary shares issued pursuant toEmployee Share Plan.1,500,000 unlisted options exercisable at $0.10 each on orbefore 1 December 2022.1,500,000 unlisted options exercisable at $0.085 each on orbefore 27 November 2023.2. 2,790,000 fully paid ordinary shares.
Class	1. Fully paid ordinary shares
Number acquired	222,223
Number disposed	-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration	$30,000
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
No. of securities held after	1. 222,223 fully paid ordinary shares
change	1,000,000 fully paid ordinary shares issued pursuant to
	Employee Share Plan.
	1,500,000 unlisted options exercisable at $0.10 each on or
	before 1 December 2022.
	1,500,000 unlisted options exercisable at $0.085 each on or
	before 27 November 2023.
	2. 2,790,000 fully paid ordinaryshares.
Nature of change	Issue of shares pursuant to share purchase plan.
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Note: In the case of a company, interests which come withindisclosed in this part.	paragraph (ii) of the definition of “notifiable interest of a director” should be
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to	N/A
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed	No
above traded during a+closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2